Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NBIX with free AI briefings, catalyst countdowns, and dilution alerts.

NBIX · NEUROCRINE BIOSCIENCES INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$789.7M Cash on Hand
CF+ Cash Runway
Follow NBIX by email Get an email when NBIX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NBIX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Valbenazine
FDA approved Apr 2017 · Ingrezza
Schizophrenia Phase 4 · NCT07105111 Recruiting
Crinecerfont
FDA approved Dec 2024 · Crenessity
Congenital Adrenal Hyperplasia Phase 3 · NCT04490915 Active not recruiting
NBI-1117568 Schizophrenia Phase 3 · NCT06963034 Recruiting
NBI-1065845 Major Depressive Disorder Phase 3 · NCT06786624 Recruiting
Infacort Adrenal Insufficiency Phase 3 · NCT02733367 Completed
Osavampator Major Depressive Disorder Phase 3 · NCT07196501 Recruiting
Chronocort Congenital Adrenal Hyperplasia Phase 3 · NCT05063994 Completed
Plenadren Primary Adrenal Insufficiency Phase 2 · NCT05222152 Completed
NBIP-01435 Congenital Adrenal Hyperplasia Phase 2 · NCT07850739 Not yet recruiting
NBI-921352 SCN8A Developmental and Epileptic Encephalopathy Syndrome Phase 2 · NCT05226780 Terminated
NBI-827104 Epileptic Encephalopathy Phase 2 · NCT05301894 Terminated
NBI-1117570 Schizophrenia Phase 2 · NCT07288333 Recruiting
NBI-1117567 Alzheimer's Disease Phase 2 · NCT07832383 Not yet recruiting
NBI-1070770 Major Depressive Disorder Phase 2 · NCT06267846 Completed
NBI-1065890 Tardive Dyskinesia Phase 2 · NCT07365462 Recruiting
NBIB-0000223 Friedreich's Ataxia Phase 1 · NCT07934303 Not yet recruiting

Also used in these trials (approved or third-party drugs, not NBIX's own candidates): Hydrocortisone, Therapeutic Hydrocortisone, Hydrocortisone modified release capsules, i.v. Hydrocortisone Injection, Hydrocortisone granules, Testosterone Undecanoate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NBIX holds $789.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NBIX files for a raise →

👥 Who Owns NBIX

Insiders 1% Institutions (1134 holders) 99% Public and other holders 0%
HolderTypeShares% of sharesAs of
JPMORGAN CHASE & CO. Institution (13G, 5%+) 5,300,390 5.24% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 5,257,941 5.19% 2026-03-31
Vanguard Portfolio Management Institution (13G, 5%+) 5,083,540 5.02% 2026-09-30
Kevin Charles Gorman
Director · +5,248 options
Insider 517,797 0.51% 2026-09-11
Kyle Gano
Chief Executive Officer, Director · +1,228 options
Insider 155,010 0.15% 2026-11-01
Eric Benevich
Chief Commercial Officer
Insider 67,297 0.07% 2026-09-11
Darin Lippoldt
Chief Legal Officer · +4,965 options
Insider 56,793 0.06% 2026-09-11
Eiry Roberts
Chief Medical Officer · +9,820 options
Insider 51,331 0.05% 2026-09-28
Matt Abernethy
Chief Financial Officer
Insider 42,808 0.04% 2026-09-11
Julie Cooke
Chief Human Resources Officer
Insider 24,025 0.02% 2026-09-11
Jude Onyia
Chief Scientific Officer · +13,268 options
Insider 22,647 0.02% 2026-09-11
Ingrid Delaet
Chief Regulatory Officer · +7,478 options
Insider 18,289 0.02% 2026-09-11

Share count 101,218,643 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NBIX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBIX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.